Allergan's BOTOX Wins FDA Nod For Neurologic Condition-Associated Pediatric Detrusor Overactivity


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


  • The FDA has approved Allergan and AbbVie Inc's (NYSE: ABBV) BOTOX (onabotulinumtoxinA). It is used to treat detrusor (bladder muscle) overactivity associated with a neurologic condition in pediatric patients five years of age and older who have an inadequate response to or are intolerant of anticholinergic medication.
  • Neurogenic detrusor overactivity occurs when the spinal cord and bladder are not able to communicate effectively. As a result, the bladder muscle involuntarily contracts, increasing the bladder's pressure and reducing the bladder capacity, which can cause the individual to leak urine frequently and unexpectedly.
  • Price Action: ABBV share are down 0.68% at $104.68 on the last check Wednesday.

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechNewsHealth CareFDAGeneralBOTOX